| We have working groups with the Directorate-General for Public Health, the Directorate-General for Mental Health and Addictions, and the Directorate-General for Pharmacy of the Generalitat Valenciana [Valencia Regional Government]. | HIV
> HIV | Regulatorisk partnerskap
> Samarbeid med regulatoriske myndigheter | 5 000 | Local | Regularly | 119026705868 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Pasientadvokasi
> Pasientrettigheter | Regulatorisk partnerskap
> Samarbeid med regulatoriske myndigheter | 10 000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Respiratorisk
> Lungefibrose | Regulatorisk partnerskap
> Samarbeid med regulatoriske myndigheter | 1 000 | National | Regularly | 119075356350 |
| IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report]. | Nevromuskulær
> Duchenne | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 5 000 | National | Regularly | 119045011464 |
| We participate in Health Technology Assessments for certain medicines. | Pasientadvokasi
> Pasientrettigheter | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | We do not communicate with patients directly | National | Rarely | 119049693177 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Pasientadvokasi
> Pasientrettigheter | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 10 000 | National | Sometimes | 119073823192 |
| We have recently completed IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report] assessments for Anifrolumab [for adults with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)] and Voclosporin [used to treat lupus nephritis].We are currently engaged in the IPT process for Obinutuzumab [used to treat specific blood cancers and active lupus nephritis]. | Reumatisk
> Lupus | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 000 | National | Regularly | 119076492282 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | Pasientadvokasi
> Pasientrettigheter | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | We do not communicate with patients directly | National | Regularly | 119012238994 |
| Community of Madrid, Department of Education, Department of Health. | Blødning
> Blødningsforstyrrelser: de fleste typer | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 5 000 | Regional | Regularly | 119012535987 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | Eldre mennesker
> Eldre mennesker | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | We do not communicate with patients directly | National | Regularly | 119013803044 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | Sjelden
> Sjeldne sykdommer: metabolske/lysosomale | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 100 | National | Rarely | 119022231157 |
| We actively participate in meetings with the Ministry of Health, including with the HIV Control Division — covering viral hepatitis, tuberculosis, and other STIs [ITS, Infecciones de Transmisión Sexual – Sexually Transmitted Infections] — as well as with the Directorate-General for Pharmacy, among others. | HIV
> HIV | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 100 000 | National | Regularly | 119036696548 |
| New therapeutic targets and State Health Council. | Reumatisk
> Revmatiske sykdommer: de fleste typer | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 10 000 | National | Regularly | 119062924366 |
| Ministry of Health. | Kardiovaskulær
> Kardiovaskulære & hjertetilstander | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 5 000 | National | Sometimes | 119072934071 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Pasientadvokasi
> Pasientrettigheter | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 10 000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Respiratorisk
> Lungefibrose | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 1 000 | National | Regularly | 119075356350 |
| Not in my capacity as President of ACPA [Asociación Canaria de Pacientes - Canary Islands Patients’ Association], but rather as a member of the POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] Patient Platform and as President of Feasam [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia]. | Kardiovaskulær
> Kardiovaskulære & hjertetilstander | Regulatorisk partnerskap
> Med andre helseadvokater | 100 | National | No | 119053738286 |
| Through ACCU [Asociaciones de Crohn y Colitis Ulcerosa - Crohn’s and Ulcerative Colitis Associations] Spain. | Gastrointestinal
> Gastrointestinal: annet | Regulatorisk partnerskap
> Med andre helseadvokater | 1 000 | Regional | Sometimes | 119053970542 |
| FEDER [Federación Española de Enfermedades Raras – Spanish Federation of Rare Diseases] and EURORDIS [European Rare Disease Organisation]. | Sjelden
> Wilsons sykdom | Regulatorisk partnerskap
> Med andre helseadvokater | 100 | National | Regularly | 119078667611 |
| Legislation pertaining to patients living with a rare disease. | Sjelden
> Sjeldne lidelser: genetisk | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 1 000 | National | Regularly | 119012112198 |
| Legal, policy, institutional, and corporate actions. | Pasientsikkerhet
> Iatrogen | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 1 000 | National | Regularly | 119045262726 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Cøliaki | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 100 000 | National | Regularly | 119053766557 |
| Letters were submitted to the Ministry of Health. | Sjelden
> Sjeldne lidelser: genetisk | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 100 | National | Regularly | 119065350505 |
| In our country [Spain] it is challenging, but we do have channels through which we are able to communicate. | Lever
> Leversykdommer: transplantasjoner | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 5 000 | National | Rarely | 119069515067 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Respiratorisk
> Lungefibrose | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 1 000 | National | Regularly | 119075356350 |
| Ongoing contact and coordination with César Hernández [Director General of the Common Portfolio of the NHS and Pharmacy within the Spanish Ministry of Health]. | Sjelden
> Sjeldne sykdommer: de fleste typer | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 100 000 | National | Regularly | 119078056907 |
| In the Community of Madrid, we are consulted on medicines and their importance for our patient community. | Blødning
> Blødningsforstyrrelser: de fleste typer | Påvirkning av politikk og lovgivning
> Delta i offentlige høringer og konsultasjoner | 5 000 | Regional | Regularly | 119036712634 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronisk
> Kroniske sykdommer generelt | Påvirkning av politikk og lovgivning
> Delta i offentlige høringer og konsultasjoner | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Cøliaki | Påvirkning av politikk og lovgivning
> Delta i offentlige høringer og konsultasjoner | 100 000 | National | Regularly | 119053766557 |
| We do not intervene in pricing decisions; however, we advocate for patient and stakeholder interests before the relevant public authorities. | Nevrologisk
> Multippel sklerose | Påvirkning av politikk og lovgivning
> Delta i offentlige høringer og konsultasjoner | 5 000 | Local | Regularly | 119064523376 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Cøliaki | Påvirkning av politikk og lovgivning
> Mobiliser parlamentarikere og politiske ledere | 100 000 | National | Regularly | 119053766557 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | HIV
> HIV | Påvirkning av politikk og lovgivning
> Mobiliser parlamentarikere og politiske ledere | 5 000 | Local | Regularly | 119072832940 |
| Through the political action initiatives we undertake and promote. | Sjelden
> Sjeldne lidelser: genetisk | Påvirkning av politikk og lovgivning
> Mobiliser parlamentarikere og politiske ledere | 100 | International | Regularly | 119078207611 |
| Legislation pertaining to patients living with a rare disease. | Sjelden
> Sjeldne lidelser: genetisk | Påvirkning av politikk og lovgivning
> Tal pasientvernlovforslag og rettigheter | 1 000 | National | Regularly | 119012112198 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Cøliaki | Påvirkning av politikk og lovgivning
> Bidra til utarbeidelse av folkehelseregelverket | 100 000 | National | Regularly | 119053766557 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | Kreft
> Kreft: bukspyttkjertel | Påvirkning av politikk og lovgivning
> Håndtering av barrierer/anomalier i medisinsk behandling | 1 000 | National | Rarely | 119012120290 |
| Nucleoside therapy for TK2d has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | Sjelden
> Sjeldne lidelser: genetisk | Prising og tilgjengelighetsadvokatur
> Gå inn for rettferdig medisinprising | 100 | National | Regularly | 119070360428 |
| Reimbursement of biological treatments. | Respiratorisk
> KOLS | Prising og tilgjengelighetsadvokatur
> Gå inn for rettferdig medisinprising | 1 000 | National | Regularly | 119078128994 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronisk
> Kroniske sykdommer generelt | Prising og tilgjengelighetsadvokatur
> Delta i forhandlinger med prisrevisjonsnemnd | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Nucleoside therapy for TK2d [Thymidine Kinase 2 deficiency] has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | Sjelden
> Sjeldne lidelser: genetisk | Prising og tilgjengelighetsadvokatur
> Delta i forhandlinger med prisrevisjonsnemnd | 100 | National | Regularly | 119070360428 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | Sjelden
> Sjeldne sykdommer: metabolske/lysosomale | Prising og tilgjengelighetsadvokatur
> Arbeide for inkludering av produkt i refusjonslister/nasjonale formularer | 100 | National | Rarely | 119022231157 |
| The priority is not so much determining the price, but securing reimbursement. | Respiratorisk
> Luftveier: de fleste tilstander | Prising og tilgjengelighetsadvokatur
> Arbeide for inkludering av produkt i refusjonslister/nasjonale formularer | 5 000 | National | Regularly | 119054105408 |
| … Reimbursement of biological therapies. | Respiratorisk
> KOLS | Prising og tilgjengelighetsadvokatur
> Arbeide for inkludering av produkt i refusjonslister/nasjonale formularer | 1 000 | National | Regularly | 119078128994 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | Kreft
> Kreft: bukspyttkjertel | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 1 000 | National | Rarely | 119012120290 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | Pasientadvokasi
> Pasientrettigheter | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | We do not communicate with patients directly | National | Regularly | 119012238994 |
| We participate in the sampling of products entering public tender processes. | Endokrin
> Diabetes (både type 1 og type 2) | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 5 000 | Regional | Regularly | 119019803062 |
| We successfully halted the withdrawal of public reimbursement for SYSADOAs [Symptomatic Slow-Acting Drugs for Osteoarthritis], an effective and well-established treatment for osteoarthritis. | Bein
> Artrose og osteoporose | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 5 000 | National | Regularly | 119022568142 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronisk
> Kroniske sykdommer generelt | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Removal of the prior authorisation requirement for triple therapy [Doctors in Spain needed administrative approval from the National Health System to prescribe or fully reimburse a combined respiratory drug in a single inhaler.] | Respiratorisk
> KOLS | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 1 000 | National | Regularly | 119078128994 |
| Providing guidance from the patient perspective. | Sjelden
> Sjeldne sykdommer: de fleste typer | Evidensbasert pasientinnspill
> Bruk pasientinnsikt til å informere beslutninger | 1 000 | National | Regularly | 119055416525 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Pasientadvokasi
> Pasientrettigheter | Evidensbasert pasientinnspill
> Bruk pasientinnsikt til å informere beslutninger | 10 000 | National | Sometimes | 119073823192 |
| They consult us. | Nevrologisk
> Fibromyalgi | Evidensbasert pasientinnspill
> Bruk pasientinnsikt til å informere beslutninger | Do not know | Local | Sometimes | 119075536668 |
| ... Advise from the patient's perspective. Influence through formal participation or institutional pressure. Contribute social evidence and patient experience. Contributing real-world evidence and patient experience. | Sjelden
> Sjeldne sykdommer: de fleste typer | Evidensbasert pasientinnspill
> Gi Real-World Evidence (RWE) til regulatoriske myndigheter | 1 000 | National | Regularly | 119055416525 |
| ... Contributing real-world evidence and patient experience. | Sjelden
> Sjeldne sykdommer: de fleste typer | Evidensbasert pasientinnspill
> Bruk pasienthistorier og fortellinger fra levd erfaring | 1 000 | National | Regularly | 119055416525 |
| Associations of family members of patients with Alzheimer's disease [interacting with drug regulators]. | Nevrodegenerativ
> Alzheimers | Evidensbasert pasientinnspill
> Bruk pasienthistorier og fortellinger fra levd erfaring | We do not communicate with patients directly | Regional | Regularly | 119067801531 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronisk
> Kroniske sykdommer generelt | Evidensbasert pasientinnspill
> Oversett bevis og innsikt til politikkinnspill | We do not communicate with patients directly | National | Regularly | 119052165521 |
| … We raise concerns on issues such as adverse drug reactions. | Eldre mennesker
> Eldre mennesker | Diagnose og medisinlevering
> Sikre trygg og effektiv legemiddelbruk | We do not communicate with patients directly | National | Regularly | 119013803044 |
| By providing information on the indications for which administration of the orphan medicinal product is clearly necessary, as well as the circumstances in which alternative forms of healthcare provision may be expected or appropriate. | Sjelden
> Von Hippel-Lindaus syndrom | Diagnose og medisinlevering
> Sikre trygg og effektiv legemiddelbruk | 100 | National | Rarely | 119046844450 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Pasientadvokasi
> Pasientrettigheter | Diagnose og medisinlevering
> Sikre trygg og effektiv legemiddelbruk | 10 000 | National | Sometimes | 119073823192 |
| … We also issue practice recommendations for members of the ESGG [Sociedad Española de Geriatría y Gerontología – Spanish Society of Geriatrics and Gerontology]. | Eldre mennesker
> Eldre mennesker | Diagnose og medisinlevering
> Delta i utvikling av kliniske retningslinjer | We do not communicate with patients directly | National | Regularly | 119013803044 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | Eldre mennesker
> Eldre mennesker | Institusjonell styring
> Sikre representasjon i statlige rådgivende organer | We do not communicate with patients directly | National | Regularly | 119013803044 |
| With public authorities. | Blødning
> Hemofili | Institusjonell styring
> Sikre representasjon i statlige rådgivende organer | 100 | Regional | Regularly | 119053275561 |
| Not directly through ACPA [Asociación Comarcal de Personas con Ansiedad - Regional Association of People with Anxiety], but through Rafael Martínez in his capacity as President of FEASAM [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia] and as a member of the POP [Patients’ Organisations Platform - Plataforma de Organizaciones de Pacientes] Patient Platform. | Kardiovaskulær
> Kardiovaskulære & hjertetilstander | Institusjonell styring
> Sikre representasjon i statlige rådgivende organer | 100 | Local | No | 119053750627 |
| Providing guidance from the patient perspective. Exercising influence through formal participation or institutional advocacy. | Sjelden
> Sjeldne sykdommer: de fleste typer | Institusjonell styring
> Sikre representasjon i statlige rådgivende organer | 1 000 | National | Regularly | 119055416525 |
| We do not intervene in pricing decisions; however, we do represent and defend the interests of those we advocate for before the relevant public authorities. | Nevrologisk
> Multippel sklerose | Institusjonell styring
> Sikre representasjon i statlige rådgivende organer | 5 000 | Local | Regularly | 119064523376 |
| We represent the interests of patients, but we do not intervene in pricing decisions. | Nevrologisk
> Multippel sklerose | Institusjonell styring
> Sikre representasjon i statlige rådgivende organer | 10 000 | Regional | Rarely | 119065344758 |
| We are members of the Patient Committee of the Valencian Community. | HIV
> HIV | Institusjonell styring
> Sikre representasjon i statlige rådgivende organer | 10 000 | Regional | No | 119072419533 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | HIV
> HIV | Institusjonell styring
> Sikre representasjon i statlige rådgivende organer | 5 000 | Local | Regularly | 119072832940 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Pasientadvokasi
> Pasientrettigheter | Institusjonell styring
> Sikre representasjon i statlige rådgivende organer | 10 000 | National | Sometimes | 119073823192 |
| The organisation has held Public Interest status, as designated by the Spanish Ministry of the Interior, since 2008. | Nevrologisk
> Nevrologisk: de fleste tilstander | Institusjonell styring
> Opprettholde formell status som allmennyttig eller veldedig enhet | 1 000 | Local | Rarely | 119054524092 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. | HIV
> HIV | Institusjonell styring
> Opprettholde formell status som allmennyttig eller veldedig enhet | 5 000 | Local | Regularly | 119072832940 |
interaksjoner
handlinger & påvirkning
19 omtaler
